Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status approved
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 63629-5688; 49452-7523; 59116-0631; 0093-3234; 70518-0185; 51552-1044; 51927-0081; 50090-2013; 59762-5000; 62135-960; 70518-1829; 70518-3732; 0013-0102; 71610-577; 62705-0222; 62991-2704; 59762-0104; 70518-2342; 71610-706; 49964-0018; 57294-021; 50090-0086; 51927-0054; 59116-0632; 0591-0796; 23155-019; 0013-0101; 63629-9715; 38779-0176; 59116-0630; 59116-0633; 68022-7065
UNII 3XC8GUZ6CB
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Granuloma23.03.15.001; 08.01.05.0010.000303%Not Available
Guillain-Barre syndrome17.09.01.001; 11.07.01.001; 10.04.10.005--
Haematochezia24.07.02.012; 07.12.02.0030.000758%Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Haemolysis01.06.04.0020.002728%
Haemolytic anaemia01.06.03.0020.000455%Not Available
Haemolytic uraemic syndrome20.01.03.011; 01.06.02.001--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hepatic failure09.01.03.0020.000606%
Hepatic necrosis09.01.07.0020.000303%
Hepatic steatosis14.08.04.005; 09.01.07.0030.000303%Not Available
Hepatitis09.01.07.0040.000909%Not Available
Hepatitis acute09.01.07.0050.000606%Not Available
Hepatitis cholestatic09.01.01.002--Not Available
Hepatitis fulminant09.01.07.007; 11.07.01.003--Not Available
Hepatocellular injury09.01.07.008--Not Available
Hepatomegaly09.01.05.0010.000455%Not Available
Hepatosplenomegaly09.01.05.002; 01.09.03.0010.000455%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
Hyperaesthesia23.03.03.080; 17.02.06.004--Not Available
Hyperphagia07.01.06.018; 19.09.01.005; 14.03.01.007--Not Available
Hypersensitivity10.01.03.0030.007880%
Hypersensitivity vasculitis01.01.04.008; 24.12.04.013; 23.06.02.005; 10.02.02.0170.000303%Not Available
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypoprothrombinaemia01.01.01.001--Not Available
Idiopathic pulmonary fibrosis22.01.02.014; 10.02.01.034--Not Available
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Infertility21.03.02.001--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene